Mielnicki L M, Ying A M, Head K L, Asch H L, Asch B B
Department of Experimental Pathology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, New York 14263, USA.
Exp Cell Res. 1999 May 25;249(1):161-76. doi: 10.1006/excr.1999.4461.
Gelsolin is a multifunctional, actin-binding protein that is greatly decreased in many transformed cell lines and tumor tissues, including breast cancers. Downregulation of gelsolin RNA occurs in most breast cancers of rats, mice, and humans, but gross mutations of the gelsolin gene have not been found. Here we demonstrate by PCR and RT-PCR analysis that there are no point mutations in putative regulatory regions or the entire coding region of the cytoplasmic isoform of the gelsolin gene in human breast cancer cells (BCC). To determine if epigenetic modification is involved in downregulating gelsolin expression in MDA-MB-231 (MDA231), MCF7, and T47D BCC, we have used Southern blot analysis, 5-azacytidine (5aza) treatment, and trichostatin A (TSA) treatment. Southern blot analysis performed on genomic DNA demonstrated altered CpG methylation within intron 1 in DNA from all BCC compared to normal, mortal human mammary epithelial cells (HMEC). Treatment of the BCC with 5aza converted the DNA restriction pattern to that seen in untreated HMEC genomic DNA and caused modest increases in gelsolin RNA and protein. Incubation with TSA, an inhibitor of histone deacetylase, induced a dramatic upregulation of gelsolin RNA and protein levels which preceded apoptotic death of all BCC within 48-60 h. Our data support a role for epigenetic changes in chromatin structure leading to downregulation of gelsolin expression in human breast cancer. To our knowledge, this is the first example of a tumor suppressor gene downregulated in human breast cancer by changes in histone acetylation.
凝溶胶蛋白是一种多功能的肌动蛋白结合蛋白,在许多转化细胞系和肿瘤组织(包括乳腺癌)中含量大幅降低。凝溶胶蛋白RNA的下调发生在大鼠、小鼠和人类的大多数乳腺癌中,但尚未发现凝溶胶蛋白基因的明显突变。在这里,我们通过PCR和RT-PCR分析证明,在人乳腺癌细胞(BCC)中,凝溶胶蛋白基因细胞质异构体的假定调控区域或整个编码区域不存在点突变。为了确定表观遗传修饰是否参与MDA-MB-231(MDA231)、MCF7和T47D BCC中凝溶胶蛋白表达的下调,我们使用了Southern印迹分析、5-氮杂胞苷(5aza)处理和曲古抑菌素A(TSA)处理。对基因组DNA进行的Southern印迹分析表明,与正常的、有限增殖的人乳腺上皮细胞(HMEC)相比,所有BCC的DNA中内含子1内的CpG甲基化发生了改变。用5aza处理BCC可使DNA限制性图谱转变为未处理的HMEC基因组DNA中的图谱,并导致凝溶胶蛋白RNA和蛋白质适度增加。用组蛋白脱乙酰酶抑制剂TSA孵育可诱导凝溶胶蛋白RNA和蛋白质水平显著上调,这在48-60小时内所有BCC凋亡死亡之前出现。我们的数据支持染色质结构表观遗传变化在导致人乳腺癌中凝溶胶蛋白表达下调方面的作用。据我们所知,这是人类乳腺癌中通过组蛋白乙酰化变化下调的肿瘤抑制基因的首个实例。